• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Rabbit anti-Human CALML4 Polyclonal Antibody

The antibody against CALML4 was raised in rabbit using the Recombinant Human Calmodulin-like protein 4 protein (1-120AA) as the immunogen. This antibody exists as a non-conjugated isotype IgG, purified by protein G with a purity greater than 95%. This antibody has been validated on ELISA, IHC.

ADC-40007A

The antibody against CALML4 was raised in rabbit using the Recombinant Human Calmodulin-like protein 4 protein (1-120AA) as the immunogen. This antibody exists as a non-conjugated isotype IgG, purified by protein G with a purity greater than 95%. This antibody has been validated on ELISA, IHC.

$299.00

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ADC-40007A ClonalityPolyclonal
Host SpeciesRabbitTarget NameCALML4
Target SynonymsCALML4 antibody; Calmodulin-like protein 4 antibody; Serologically defined breast cancer antigen NY-BR-20 antibodyFormLiquid
Species ReactivityHumanIsotypeIgG
Storage Buffer0.01M PBS, 0.03% Proclin 300; Constituents: 50% Glycerol, PH 7.4Purification Method>95%, Protein G purified
ConjugateNon-conjugatedApplicationELISA, IHC
StorageUpon receipt

Immunogen Information


Immunogen DescriptionRecombinant Human Calmodulin-like protein 4 protein (1-120AA)Target SpeciesHuman
Immunogen SequenceComplete sequences for the immunogen, target protein, and peptides are available upon request.Uniprot IDQ96GE6
Background Information
  • Uniprot Id

    Q96GE6

  • Target Species

    Human

  • Target Name

    CALML4

  • Target Full Name

    Calmodulin-like protein 4

  • Target Synonyms

    CALML4; Calmodulin-like protein 4; Serologically defined breast cancer antigen NY-BR-20

Inquire Rabbit anti-Human CALML4 Polyclonal Antibody Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification